BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23770604)

  • 1. An improved route to 19-substituted geldanamycins as novel Hsp90 inhibitors--potential therapeutics in cancer and neurodegeneration.
    Kitson RR; Moody CJ
    Chem Commun (Camb); 2013 Oct; 49(76):8441-3. PubMed ID: 23770604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90.
    Kitson RR; Chang CH; Xiong R; Williams HE; Davis AL; Lewis W; Dehn DL; Siegel D; Roe SM; Prodromou C; Ross D; Moody CJ
    Nat Chem; 2013 Apr; 5(4):307-14. PubMed ID: 23511419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites.
    Lee K; Ryu JS; Jin Y; Kim W; Kaur N; Chung SJ; Jeon YJ; Park JT; Bang JS; Lee HS; Kim TY; Lee JJ; Hong YS
    Org Biomol Chem; 2008 Jan; 6(2):340-8. PubMed ID: 18175003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors.
    Li Z; Jia L; Wang J; Wu X; Hao H; Xu H; Wu Y; Shi G; Lu C; Shen Y
    Eur J Med Chem; 2014 Oct; 85():359-70. PubMed ID: 25105924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo Evaluation of 17-phenylpropylamine/phenoxyethylamine- 17-demethoxygeldanamycins as Potent Hsp90 Inhibitors.
    Li Z; Jia L; Xu H; Lu C; Shena Y
    Med Chem; 2015; 11(5):482-8. PubMed ID: 25537129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and structure--activity relationships for chimeric inhibitors of Hsp90.
    Shen G; Wang M; Welch TR; Blagg BS
    J Org Chem; 2006 Sep; 71(20):7618-31. PubMed ID: 16995666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of geldanamycin analogs against human cancer cells.
    Li YP; Chen JJ; Shen JJ; Cui J; Wu LZ; Wang Z; Li ZR
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):773-82. PubMed ID: 25681003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of diamine-linked 17-aroylamido-17-demethoxygeldanamycins as potent Hsp90 inhibitors.
    Li Z; Jia L; Wang J; Wu X; Hao H; Wu Y; Xu H; Wang Z; Shi G; Lu C; Shen Y
    Eur J Med Chem; 2014 Nov; 87():346-63. PubMed ID: 25277067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Learning from nature: advances in geldanamycin- and radicicol-based inhibitors of Hsp90.
    Kitson RR; Moody CJ
    J Org Chem; 2013 Jun; 78(11):5117-41. PubMed ID: 23496136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of reblastatin, autolytimycin, and non-benzoquinone analogues: potent inhibitors of heat shock protein 90.
    Wrona IE; Gozman A; Taldone T; Chiosis G; Panek JS
    J Org Chem; 2010 May; 75(9):2820-35. PubMed ID: 20392070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
    Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
    J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors.
    Li Z; Jia L; Wang J; Wu X; Shi G; Lu C; Shen Y
    Chem Biol Drug Des; 2015 Feb; 85(2):181-8. PubMed ID: 24903735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformational significance of EH21A1-A4, phenolic derivatives of geldanamycin, for Hsp90 inhibitory activity.
    Onodera H; Kaneko M; Takahashi Y; Uochi Y; Funahashi J; Nakashima T; Soga S; Suzuki M; Ikeda S; Yamashita Y; Rahayu ES; Kanda Y; Ichimura M
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1588-91. PubMed ID: 18243703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat shock protein 90: inhibitors in clinical trials.
    Biamonte MA; Van de Water R; Arndt JW; Scannevin RH; Perret D; Lee WC
    J Med Chem; 2010 Jan; 53(1):3-17. PubMed ID: 20055425
    [No Abstract]   [Full Text] [Related]  

  • 16. Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin.
    McErlean CS; Proisy N; Davis CJ; Boland NA; Sharp SY; Boxall K; Slawin AM; Workman P; Moody CJ
    Org Biomol Chem; 2007 Feb; 5(3):531-46. PubMed ID: 17252137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent cytotoxic C-11 modified geldanamycin analogues.
    Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y
    J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.
    Franke J; Eichner S; Zeilinger C; Kirschning A
    Nat Prod Rep; 2013 Oct; 30(10):1299-323. PubMed ID: 23934201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total synthesis of the Hsp90 inhibitor geldanamycin.
    Qin HL; Panek JS
    Org Lett; 2008 Jun; 10(12):2477-9. PubMed ID: 18489177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.